Skip to main content
. 2015 Mar 27;7(5):648–669. doi: 10.15252/emmm.201404368

Figure 4.

Figure 4

Comparison of the GI50 values of RK-33 with FDA-approved drugs on the NCI-60 panel of cell lines
  1. A, B The graph depicts the growth inhibitory properties (GI50) of RK-33 for the NCI-60 panel of cell lines. The NCI-60 is a panel of 60 extensively characterized human cell lines derived from nine distinct tumor types: melanoma, ovarian, renal, breast, leukemia, lung, prostate, colon, and CNS.
  2. C Network analysis of 102 FDA-approved drugs and RK-33 based on GI50 in the NCI-60 cell line panel.
  3. D Unsupervised cluster analysis of the 102 FDA-approved drugs based on the correlation structure of the GI50 levels. The result is shown as a symmetric heat map with positive associations depicted in yellow and negative associations shown in blue.

Data information: Error bars represent SD and all experiments were done in replicates.